Next-Generation Biotherapeutic Solutions for Tissue Repair and Regeneration
The company’s unique platform is a concentrate of proteins enriched in bromelain, which is extracted from the pineapple stem, purified and enriched utilizing our proprietary enzymes enrichment technology.
Our strategy leverages our breakthrough enzymatic technology platform into diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. Our current portfolio is focused on next-generation bio active therapies for burn and wound care and biological medicinal products for tissue repair.
MediWound’s enzyme enrichment technology (EET) harnesses nature’s wisdom while maximizing its biotherapeutic properties for medical therapies.
Enzyme enrichment technology is characterized by the ability to enrich the natural substance with its most active components while maintaining their highest activity during all process stages, from plant harvesting through the pharmaceutical product on the shelf.
From Plant to Drug
Our pharmaceutical product ingredient (API) is a complex mixture of proteins, enriched in bromelain, extracted from the stem of the pineapple. The API possess various pharmacological properties, including:
NexoBrid is our commercial biological orphan product for debridement of severe thermal burns. NexoBrid is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. Nexobrid is currently marketed in the European Union and other International markets and is at registration-stage with the United States Food and Drug Administration (FDA) with a PDUFA date set as of January 1, 2023. NexoBrid is supported by U.S. Biomedical Advanced Research and Development Authority (BARDA).
The European Medicines Agency (EMA) validated for review the Company’s Type II Variation to expand NexoBrid’s currently approved indication for the pediatric population.
EscharEx, our next-generation bioactive topical therapeutic for debridement of chronic and hard to heal wounds, is a product candidate in advanced stages of development. In three Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MW005, our biological drug for the treatment of non-melanoma skin cancer. MW005 has received positive initial data from the Company’s U.S. Phase I/II study of MW005 for the treatment of low-risk basal cell carcinoma (BCC). The initial data showed MW005 to be safe and well-tolerated, and target lesions clearance data provided clinical efficacy proof-of-concept. Additional study results by year-end.